BMS - BMY Total Debt to Capital

Pressure from the patent expiration of blockbusters is temporarily reducing margins, which is reflected in the total liabilities-to-equity ratio for Bristol-Myers Squibb (BMY). The 1.78 level serves as a critical benchmark for this metric. Stable demand for cardiology drugs guarantees a powerful cash flow, while breakthrough developments in cell therapy and immuno-oncology open new horizons in the treatment of critical pathologies.

The total debt-to-equity ratio measures the degree of financial leverage by comparing total liabilities to the net value of assets. This ratio is sensitive to changes in balance sheet structure and the cost of borrowed resources. By analyzing the dynamics of equity dependence on debt, an investor assesses the stability of the WACC model. For Bristol-Myers Squibb (BMY), this balance is critical when financing new developments, as it allows the company to offset revenue declines resulting from the loss of patent protection for key drugs.